Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Oct 24, 2014

NEW YORK (GenomeWeb) - Ruby Gadelrab has been named vice president of commercial marketing for 23andMe. Gadelrab most recently served as head of marketing and commercial development at Invitae, and prior to that had worked at Affymetrix, where she most recently served as head of international marketing and clinical development. She also has worked at Life Technologies, Dharmacon, and AbGene.

Epic Sciences has appointed Michael Giske its new chief information officer. Giske previously was director of IT strategy and architecture at Oracle, and prior to that was CEO and managing partner at KPMGS, a provider of information technology solutions and services.

Former Transgenomic President and CEO Craig Tuttle was named president of private investment firm Prairie Ventures. Tuttle was also the president of Duke Scientific, which he sold to Fisher Scientific, now part of Thermo Fisher Scientific, and was president of Applied Biotech and Seradyn within the Apogent group, now also Thermo Fisher.

Gen9 has appointed Leda Notchey as VP of marketing and Matt Marano as senior director of business development.

Notchey joins Gen9 from Thermo Fisher Scientific, where she was most recently director of global channel development, biosciences. Prior to that she was director of strategic marketing for Thermo Fisher's Laboratory Products business, and she also has held senior marketing positions at Codon Devices and PerkinElmer.

Marano previously served as director of business development at Archimedes, where he developed and led the company's commercial expansion into Europe, and he also has held positions at BioTrove, CODA Genomics, Invitrogen, Ardais Corporation, BioRobotics, Packard Instrument, and Molecular Dynamics.

BaseHealth has tapped Jorge Velarde to serve as its CEO and president. He is taking over from Hossein Fakhrai-Rad, current chairman of the board, who is now transitioning into a new role as the company's chief scientific officer.

Before taking on the role of CEO, Velarde was the interim CEO and senior vice president of business development and marketing at BaseHealth. Before he joined the company, Velarde was vice president of business development at Illumina. He also worked in business development at Gen-Probe, which was acquired by Hologic in 2012.

Cambridge Semantics has hired John Rueter as its new vice president of marketing. In the role, he'll oversee activities related to the company's corporate and product marketing as well as demand generation and product management.

Previously, Rueter served as vice president of marketing for Endeca, a provider of big data management solutions. Before that, he served as chief marketing officer of StreamServe and as senior vice president of global marketing for Fast Search & Transfer. Rueter has an MBA with a concentration in marketing and management policy from Boston University Graduate School of Management, and a bachelor’s degree from Harvard College.

Quest Diagnostics has elected Jeffrey Leiden to its Board of Directors. Leiden is the chairman, president, and CEO of Vertex Pharmaceuticals. Prior to that, he was a managing director at Clarus Ventures, and before that served as president, chief operating officer, and chief scientific officer at Abbott laboratories. He has more than 20 years of scientific and commercial experience in the pharmaceutical and biotechnology industries as well as clinical and scientific experience as a cardiologist and molecular biologist.

Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.